{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:03:42Z","timestamp":1790805822066,"version":"4.1.0"},"reference-count":137,"publisher":"Informa UK Limited","issue":"10","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Gastroenterology &amp; Hepatology"],"published-print":{"date-parts":[[2022,10,3]]},"DOI":"10.1080\/17474124.2022.2138857","type":"journal-article","created":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T08:58:05Z","timestamp":1666601885000},"page":"927-940","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Filgotinib for moderately to severely active ulcerative colitis"],"prefix":"10.1080","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1655-6762","authenticated-orcid":false,"given":"Alessandro","family":"Mannucci","sequence":"first","affiliation":[{"name":"IRCCS San Raffaele Scientific Institute","place":["Milan, Italy"]},{"name":"Vita-Salute San Raffaele University","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferdinando","family":"D\u2019Amico","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Scientific Institute","place":["Milan, Italy"]},{"name":"Vita-Salute San Raffaele University","place":["Milan, Italy"]},{"name":"Humanitas University","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"El Saadi","sequence":"additional","affiliation":[{"name":"Vita-Salute San Raffaele University","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"University of Lorraine, CHRU-Nancy","place":["Nancy, France"]},{"name":"University of Lorraine, Inserm, NGERE","place":["Nancy, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-1351","authenticated-orcid":false,"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Scientific Institute","place":["Milan, Italy"]},{"name":"Vita-Salute San Raffaele University","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,11,14]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32126-2"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30358-9"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30333-4"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2018.1511664"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gtc.2014.05.011"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm401490p"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00311.2015"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2017.1243468"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1697227"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy004"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.103"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11605-020-04832-y"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy040"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-021-01781-x"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.45"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2016-312912"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00212"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-019-0263-2"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa233"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212595"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003668"},{"key":"e_1_3_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-021-00791-1"},{"key":"e_1_3_6_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)81168-X"},{"key":"e_1_3_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.04.059"},{"key":"e_1_3_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15514"},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201348"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2020.1780120"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2019-318448"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key339"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219012"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.9055"},{"key":"e_1_3_6_35_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210105"},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210104"},{"key":"e_1_3_6_37_1","unstructured":"Jyseleca\u00ae (Filgotinib). Approved in Japan for rheumatoid arthritis. Cited 2022 Feb 6]. Available from 2022 Feb 6: https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/9\/jyseleca-filgotinib-approved-in-japan-for-rheumatoid-arthritis."},{"key":"e_1_3_6_38_1","unstructured":"Jyseleca | European Medicines Agency. Cited 2022 Feb 6]. Available from 2022 Feb 6: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jyseleca."},{"key":"e_1_3_6_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32483-8"},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32463-2"},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32537-5"},{"key":"e_1_3_6_42_1","unstructured":"Jyseleca \u00ae. \u25bc(filgotinib) approved in the European Union for the treatment of ulcerative colitis. [Cited 2022 Feb 6]. Available from: https:\/\/www.glpg.com\/press-release\/2065\/jyseleca-filgotinib-approved-in-the-european-union-for-the-treatment-of-ulcerative-colitis#:~:text=Filgotinib%20is%20also%20approved%20and therapy%20or%20a%20biologic%20agent."},{"key":"e_1_3_6_43_1","unstructured":"CHMP. Jyseleca INN-filgotinib [Cited 2022 Feb 6]. Available from: https:\/\/www.ema.europa.eu\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-jyseleca-ii-01_en.pdf"},{"key":"e_1_3_6_44_1","unstructured":"Jyseleca \u00ae approved in Japan for ulcerative colitis Approval of additional indication based on Phase 2b\/3 SELECTION study in patients with moderate-to-severe ulcerative colitis [Cited 2022 Apr]. Available from: https:\/\/www.glpg.com\/press-release\/3571\/jyseleca-approved-in-japan-for-ulcerative-colitis."},{"key":"e_1_3_6_45_1","unstructured":"Jyseleca \u00ae \u25bc (FILGOTINIB) licensed for the treatment of adult patients with moderately to severely active ulcerative colitis in Great Britain [Cited 2022 Apr]. Available from: https:\/\/www.glpg.com\/press-release\/3519\/jyseleca-filgotinib-licensed-for-the-treatment-of-adult-patients-with-moderately-to-severely-active-ulcerative-colitis-in-great-britain"},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3661"},{"key":"e_1_3_6_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0273-0"},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.9.6073"},{"key":"e_1_3_6_49_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.10.5790"},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.504126"},{"key":"e_1_3_6_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.014"},{"key":"e_1_3_6_52_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051113-024537"},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2008.08.004"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00224-09"},{"key":"e_1_3_6_55_1","article-title":"Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis","volume":"24","author":"D\u2019Amico F","year":"2021","unstructured":"D\u2019Amico F, Magro F, Peyrin-Biroulet L, et al. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohns Colitis. 2021 Jun 24;16(5):835\u2013844.","journal-title":"J Crohns Colitis"},{"key":"e_1_3_6_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2012.03.013"},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.07.038"},{"key":"e_1_3_6_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-06-164368"},{"key":"e_1_3_6_59_1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01953-2016"},{"key":"e_1_3_6_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9"},{"key":"e_1_3_6_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.537"},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0240-z"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-022-01129-y"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2020.1785868"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.659"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.870"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01439-0"},{"issue":"10","key":"e_1_3_6_68_1","first-page":"S209","article-title":"Analysis of the JAK1 selectivity of GLPG0634 and its main metabolite in different species, healthy volunteers and rheumatoid arthritis patients","volume":"65","author":"Galien R","year":"2013","unstructured":"Galien R, Vayssi\u00e8re B, De Vos S, et al. Analysis of the JAK1 selectivity of GLPG0634 and its main metabolite in different species, healthy volunteers and rheumatoid arthritis patients. Arthritis Rheum. 2013;65(Suppl 10):S209\u2013S210.","journal-title":"Arthritis Rheum"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.2174\/1872312810666151223103353"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1015"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-eular.933"},{"key":"e_1_3_6_72_1","unstructured":"(EMA) European Medicines Agency. Assessment report - Jyseleca INN-filgotinib - Annex 1. 2020 [Cited 2022 Oct]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/jyseleca-epar-product-information_en.pdf."},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13726"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00666-8"},{"key":"e_1_3_6_75_1","unstructured":"Filgotinib in long-term extension study of adults with ulcerative colitis - Full text view - ClinicalTrials.gov. [cited 2022 Feb]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02914535."},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab075.036"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.617"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.644"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.006"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2021.00143"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.618"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.076"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2016.04.039"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.001"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz455"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.11.003"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32545-0"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.064"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.05.062"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-009-9365-4"},{"key":"e_1_3_6_91_1","unstructured":"CHMP. Committee for Medicinal Products for Human Use (CHMP) assessment report. 2020 [Cited 2022 Apr]; Available from: https:\/\/www.ema.europa.eu\/en\/committees\/committee-medicinal-products-human-use-chmp"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02168-4"},{"key":"e_1_3_6_93_1","unstructured":"Study to evaluate the testicular safety of filgotinib in adult males with moderately to severely active inflammatory bowel disease - Full text view - ClinicalTrials.gov. [Cited 2022 Mar]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03201445?cond=filgotinib&draw=3&rank=20."},{"key":"e_1_3_6_94_1","unstructured":"Study to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis psoriatic arthritis ankylosing spondylitis or non-radiographic axial spondyloarthritis - Full text view - ClinicalTrials.gov. [Cited 2022 Mar]. Available from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03926195."},{"key":"e_1_3_6_95_1","unstructured":"** GALAPAGOS REPORTS PRIMARY ENDPOINT FOR THE ONGOING. [cited 2022 Apr]. Available from: https:\/\/www.globenewswire.com\/news-release\/2021\/03\/04\/2186756\/0\/en\/GALAPAGOS-REPORTS-PRIMARY-ENDPOINT-FOR-THE-ONGOING-FILGOTINIB-MANTA-AND-MANTA-RAy-SAFETY-STUDIES.html.\u2022\u2022 Preliminary evidence that the risk of male infertility is low from the MANTA and MANTA RAY studies"},{"key":"e_1_3_6_96_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01346-4"},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725"},{"key":"e_1_3_6_98_1","unstructured":"EFFICACI\u202f: efficacy of intravenous infliximab versus vedolizumab after failure of subcutaneous anti-TNF in patients with ulcerative colitis - Full text view - ClinicalTrials.gov [Cited 2022 Apr]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03679546."},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00338-1"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00294-6"},{"key":"e_1_3_6_101_1","unstructured":"Placebo-controlled study of brazikumab in participants with moderately to severely active ulcerative Colitis - Full Text view - ClinicalTrials.gov. [Cited 2022 Apr]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03616821."},{"key":"e_1_3_6_102_1","unstructured":"Open-label extension study of brazikumab in ulcerative colitis - Full text view - ClinicalTrials.gov. [Cited 2022 Apr]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04277546."},{"key":"e_1_3_6_103_1","unstructured":"A study of mirikizumab (LY3074828) in participants with ulcerative colitis - Full $$w - ClinicalTrials.gov [Cited 2022 Apr]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04469062."},{"key":"e_1_3_6_104_1","unstructured":"A maintenance study of mirikizumab in participants with moderately to severely active ulcerative colitis - Full text view - ClinicalTrials.gov [Cited 2022 Apr]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03524092."},{"key":"e_1_3_6_105_1","unstructured":"A study to evaluate the efficacy safety and pharmacokinetics of UTTR1147A compared with placebo and with vedolizumab in participants with moderate to severe ulcerative colitis (UC) - Full text view - ClinicalTrials.gov [Cited 2022 Apr]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03558152."},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15297"},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i28.4055"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00065-0"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.033"},{"key":"e_1_3_6_110_1","article-title":"Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis","volume":"47","author":"Li Y","year":"2022","unstructured":"Li Y, Yao C, Xiong MSMQ, et al. Network meta-analysis on efficacy and safety of different Janus kinase inhibitors for ulcerative colitis. J Clin Pharm Ther. 2022 Jul;47(7):851\u2013859.","journal-title":"J Clin Pharm Ther"},{"key":"e_1_3_6_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00377-0"},{"key":"e_1_3_6_112_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjac040"},{"key":"e_1_3_6_113_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab052"},{"key":"e_1_3_6_114_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_3_6_115_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2202778"},{"key":"e_1_3_6_116_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000738"},{"key":"e_1_3_6_117_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2021.1898944"},{"key":"e_1_3_6_118_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.07.042"},{"key":"e_1_3_6_119_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy191"},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz095"},{"key":"e_1_3_6_121_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.11.038"},{"key":"e_1_3_6_122_1","doi-asserted-by":"publisher","DOI":"10.1111\/tog.12271"},{"key":"e_1_3_6_123_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S303279"},{"key":"e_1_3_6_124_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S87271"},{"key":"e_1_3_6_125_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa014"},{"key":"e_1_3_6_126_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-021-01055-0"},{"key":"e_1_3_6_127_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05226-w"},{"key":"e_1_3_6_128_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14341"},{"key":"e_1_3_6_129_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12919-021-00230-7"},{"key":"e_1_3_6_130_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-018-1925-8"},{"key":"e_1_3_6_131_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068"},{"key":"e_1_3_6_132_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.755"},{"key":"e_1_3_6_133_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab232.375"},{"key":"e_1_3_6_134_1","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac015.167"},{"key":"e_1_3_6_135_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.08.017"},{"key":"e_1_3_6_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(19)39173-5"},{"key":"e_1_3_6_137_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2021.03.034","article-title":"Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis","volume":"20","author":"Ahmed W","year":"2022","unstructured":"Ahmed W, Galati J, Kumar A, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022 Mar;20(3):e361\u2013e379.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_3_6_138_1","unstructured":"A study of efficacy and safety of combination therapy with Guselkumab and Golimumab in participants with moderately to severely active ulcerative colitis - Full text view - ClinicalTrials.gov [Cited 2022 Apr]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03662542."},{"key":"e_1_3_6_139_1","unstructured":"Triple combination therapy in high risk Crohn\u2019s Disease (CD) - Full text view - ClinicalTrials.gov [Cited 2022 Apr]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02764762."}],"container-title":["Expert Review of Gastroenterology &amp; Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474124.2022.2138857","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:29:50Z","timestamp":1770899390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474124.2022.2138857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":137,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10,3]]}},"alternative-id":["10.1080\/17474124.2022.2138857"],"URL":"https:\/\/doi.org\/10.1080\/17474124.2022.2138857","relation":{},"ISSN":["1747-4124","1747-4132"],"issn-type":[{"value":"1747-4124","type":"print"},{"value":"1747-4132","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierh20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierh20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-06-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}